HEALTH & SCIENCE — Researchers have uncovered new details about how the blood-brain barrier selectively allows certain proteins from the bloodstream to enter the brain, challenging the simplified view that the barrier functions mainly as a wall that blocks substances. The study, published in Cell and indexed by the U.S. National Library of Medicine, identified a group of circulating proteins that can cross the barrier and reach specific brain cells.

Scientific diagram illustrating transport of blood proteins across barriers into the brain
Illustrative diagram of blood-to-brain protein transport. Source: Frontiers in Physiology (2021); image is not a figure from the new study.

Using a method called bioorthogonal proteomics, the research team examined 191 proteins in blood plasma and found that 92 were transported into brain tissue under healthy conditions. The proteins were not distributed randomly: some were associated with particular brain cell types. The findings are detailed in the published scientific abstract.

One protein attracted particular attention: apolipoprotein A1, or APOA1. The researchers reported that it crosses the blood-brain barrier through a receptor known as SR-B1 and then interacts with the ABCA1 transporter in astrocytes, brain support cells involved in maintaining the environment around neurons. This pathway helps regulate cholesterol movement and supports the integrity of connections between nerve cells, according to the study’s findings.

The team also investigated early-stage Alzheimer’s disease models in mice and observed changes in the transport of selected proteins, including reduced APOA1 delivery to the brain. Increasing APOA1 production in the liver restored its levels in the mouse brain and improved several measured brain-cell and behavioural outcomes. These are preclinical findings in animal models, not evidence that the approach treats or prevents Alzheimer’s disease in people; the distinction is important when interpreting the research results.

The work could help scientists understand how communication between the body and brain changes during neurodegenerative disease. It may also inform future research into therapeutic delivery across the blood-brain barrier, a longstanding challenge in medicine. Clinical studies will be needed before the findings can be translated into human treatments, as the published study is based on laboratory methods and mouse models.